Portal de Periódicos da CAPES

Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule

1991; Taylor & Francis; Volume: 6; Issue: 1 Linguagem: Inglês

10.3109/10428199109064880

1042-8194

Stuart M. Lichtman, Abraham Mittelman, Daniel R. Budman, Carmelo Puccio, Hoo G. Chun, Steven L. Allen, Tauseef Ahmed, Zalmen A. Arlin,

Protein Degradation and Inhibitors

A phase II trial of fludarabine phosphate using a bolus and continuous infusion regimen in previously treated multiple myeloma was performed. No responses were observed in eleven patients. There was no significant non-hematologic toxicity noted. Fludarabine phosphate is inactive in multiple myeloma using this schedule.